BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 19005406)

  • 1. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
    Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Roza A
    Am J Transplant; 2003 Mar; 3(3):306-11. PubMed ID: 12614286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.
    Parrott NR; Hammad AQ; Watson CJ; Lodge JP; Andrews CD
    Transplantation; 2005 Feb; 79(3):344-8. PubMed ID: 15699766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
    Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
    Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of graft function in pediatric kidney transplantation is not affected by delayed introduction of cyclosporine.
    Cransberg K; Bouts AH; Cornelissen EA; Lilien MR; Van Hoeck KJ; Hop WC; Nauta J
    Transplantation; 2008 Nov; 86(9):1199-205. PubMed ID: 19005400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T; Sato S; Koyama I; Nanmoku K; Sekijima M; Tonsyo M; Kai K; Kato Y; Urashima Y; Nakajima I; Fuchinoue S; Teraoka S
    Transplant Proc; 2005 Mar; 37(2):895-8. PubMed ID: 15848568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
    Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
    Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids.
    Turconi A; Rilo LR; Goldberg J; de Boccardo G; Garsd A; Otero A
    Transplant Proc; 2005 Mar; 37(2):672-4. PubMed ID: 15848497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
    Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.
    Mehra MR; Zucker MJ; Wagoner L; Michler R; Boehmer J; Kovarik J; Vasquez A
    J Heart Lung Transplant; 2005 Sep; 24(9):1297-304. PubMed ID: 16143248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.